NCT05467722View on ClinicalTrials.gov

Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543

PHASE1CompletedINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

June 1, 2022

Primary Completion Date

September 15, 2022

Study Completion Date

September 21, 2022

Conditions
Hepatic Impairment
Interventions
DRUG

CTP-543

Single 12 mg oral dose administered on Day 1

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

37920

Alliance for Multispecialty Research, LLC, Knoxville

Sponsors
All Listed Sponsors
lead

Concert Pharmaceuticals

INDUSTRY

NCT05467722 - Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of CTP-543 | Biotech Hunter | Biotech Hunter